NEW YORK (360Dx) – Qiagen and DiaSorin said on Monday that their jointly developed automated workflow for latent tuberculosis testing has received CE marking.

Under a partnership announced earlier this year, the companies developed the Liaison QuantiFeron-TB Plus workflow, which involves processing Qiagen's QuantiFeron-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) on DiaSorin's Liaison immunodiagnostic instruments.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.